ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Aug 12, 2025
– Data from ASPEN-06 trial highlights CD47 expression as a key predictive biomarker of greater response to evorpacept in HER2+ Gastric Cancer; updated data to be presented at a medical conference in Q4 2025
Read more at globenewswire.com
